Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSchroder Japan Regulatory News (SJG)

Share Price Information for Schroder Japan (SJG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 251.00
Bid: 250.00
Ask: 251.00
Change: 4.00 (1.62%)
Spread: 1.00 (0.40%)
Open: 250.00
High: 251.00
Low: 249.00
Prev. Close: 247.00
SJG Live PriceLast checked at -
Schroder Japan Growth is an Investment Trust

To achieve capital growth from an actively managed portfolio principally comprising securities listed on the Japanese stock markets.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results analysis from Kepler Trust Intelligence

2 Oct 2023 12:43

RNS Number : 3964O
Schroder Japan Trust PLC
02 October 2023
 

Schroder Japan Trust (SJG)

02/10/2023

Results analysis from Kepler Trust Intelligence

Schroder Japan Trust (SJG) has reported strong absolute and relative returns for the year ending 31/07/2023, with a NAV total return of 11.7%, well ahead of the 9.4% total return of the benchmark. The share price total return was 18.7%, as the discount narrowed. It was the third consecutive year the trust has outperformed the Topix Index benchmark.

The trust is therefore substantially ahead of its tender performance target. This is to outperform the index by 2% a year over the four years from 01/08/2020. With one year left, the manager has delivered c. 4% of annualised outperformance so far.

During the year, the trust's name was changed, with the board dropping 'Growth' in order to 'reflect more accurately the investment approach of the manager'.

Manager Masaki Taketsume's investment strategy sees him place importance on valuation, and this was helpful during the year as value outperformed growth in Japan. There were strong returns from financials and some idiosyncratic stories where the manager identified short-term over-reaction in strong companies. Gearing also contributed positively to returns during the year.

In order to lower the costs of gearing, the board is asking for shareholder approval to allow the manager to use contracts for difference in addition to bank borrowings.

Revenue during the year increased from 4.97p to 5.41p per share, allowing the board to declare a final dividend for the year of 5.40p per share, representing an increase of 10% over the final dividend paid in 2022. At the time of writing, this would amount to a yield of 2.3% on the current share price.

Chairman of the board Philip Kay said: "My fellow directors and I continue to be excited about the company's prospects, because we see two major developments which should continue to drive equity performance over the medium to long term. Firstly, corporate governance and stock market reforms in recent years have stimulated a tectonic shift in the attitude of many Japanese companies towards improving returns for shareholders. Secondly, the reappearance of inflation could signal the end of the deflationary spiral which has, for example, constrained consumer spending in Japan over the last two decades. ... Against this macroeconomic background, there remain significant opportunities for our high conviction, bottom-up strategy to identify and exploit market opportunities and drive positive relative performance."

Kepler View

These are excellent results from Schroder Japan Trust (SJG) which show shareholders have been rewarded for remaining invested while sentiment towards the global economy has been negative. To some extent the trust's sturdy total returns reflect that Japan has been at a different point in the cycle from its developed world peers. It only lifted its last pandemic-era restrictions in Q4 2022, and so there has been a rise in domestic economic activity and tourism in 2023, with the end of China's zero-COVID policy late last year also providing visitors and demand for goods and services. This is one of the reasons for growing investor interest in the country this year.

However, we think the more important, and potentially longer-term, reason is the one highlighted by the chairman in his comments: corporate governance reform is only gathering pace and momentum, and encouraging more efficient use of cash in Japanese businesses, either to generate growth or to distribute to shareholders. We think this could lead to the valuation gap Japanese equities trade on versus their international peers to close, which means opportunity at the index level. Crucially, it is also creating great opportunity at the stock-specific level, rewarding investors with a local presence (like Schroders) who can identify those company management teams committed to significant change that can lead to individual stock re-ratings.

Masaki's strategy is to find high quality companies whose value is not reflected in the current share price. Returns over the last year show how this can generate returns from multiple sources. Financial positions performed well as Japan inched towards tightening monetary policy, raising the possibility it would escape the deflationary environment which has limited economic growth over many years. More interesting are the idiosyncratic positions such as Ibiden. Ibiden is a small cap electronic component manufacturer whose products are critical for CPUs and GPUs. Masaki built a position last year on weakness and was rewarded this year when AI-linked stocks rallied sharply. Similarly Disco Corporation has a strong market share in providing equipment for integrated circuit packaging, used in the semi-conductor industry. It also contributed strongly to returns over the period. We think these examples illustrate Japan has many interesting technology companies flying under the radar of most global investors.

We think it is intriguing to note that Japanese equities remain cheaper than many international peers while there are many companies trading below book value, even though the Topix hit all-time highs over the year in question. An example of the latter is mid-cap Mitsui Chemicals, which Masaki bought for Schroder Japan Trust in the 2023 financial year. Management have a plan to transform the company operationally which has seen it deliver resilient earnings even as demand slows, Masaki arguing that this indicates the transformation is already bearing fruit and this has not been reflected in the share price.

All told, low valuations, a cyclical boost from the reopening and the long-term trend of improved corporate governance create an exciting environment to be investing in Japan, and in our view Schroder Japan Trust has shown its valuation-sensitive stock-picking strategy has the potential to add value in such an environment.

CLICK HERE TO READ THE FULL REPORT  Visit Kepler Trust Intelligence for more high quality independent investment trust research.

Important information

This report has been issued by Kepler Partners LLP.  The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.  

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADZMGGMZZGFZM
Date   Source Headline
25th Nov 202111:13 amRNSNet Asset Value(s)
24th Nov 202111:00 amRNSNet Asset Value(s)
23rd Nov 202111:38 amRNSNet Asset Value(s)
22nd Nov 202111:42 amRNSNet Asset Value(s)
19th Nov 202111:49 amRNSNet Asset Value(s)
18th Nov 202111:26 amRNSNet Asset Value(s)
17th Nov 20215:11 pmRNSHolding(s) in Company
17th Nov 20214:39 pmRNSDirector/PDMR Shareholding
17th Nov 20212:59 pmRNSDirector/PDMR Shareholding
17th Nov 202111:17 amRNSNet Asset Value(s)
16th Nov 202111:39 amRNSNet Asset Value(s)
15th Nov 20213:04 pmRNSDirector/PDMR Shareholding
15th Nov 202111:10 amRNSNet Asset Value(s)
12th Nov 20214:12 pmRNSInvestor Webinar - 2 December 2021
12th Nov 202111:26 amRNSNet Asset Value(s)
11th Nov 202111:20 amRNSNet Asset Value(s)
10th Nov 20211:52 pmRNSHolding(s) in Company
10th Nov 202111:46 amRNSNet Asset Value(s)
9th Nov 202111:10 amRNSNet Asset Value(s)
8th Nov 202112:09 pmRNSNet Asset Value(s)
5th Nov 202111:20 amRNSNet Asset Value(s)
4th Nov 202111:11 amRNSNet Asset Value(s)
3rd Nov 202111:56 amRNSNet Asset Value(s)
2nd Nov 202111:26 amRNSNet Asset Value(s)
1st Nov 202111:31 amRNSNet Asset Value(s)
29th Oct 202111:31 amRNSNet Asset Value(s)
28th Oct 202111:53 amRNSNet Asset Value(s)
27th Oct 20213:27 pmRNSPortfolio Update
27th Oct 202111:38 amRNSNet Asset Value(s)
27th Oct 20217:02 amRNSDividend Declaration
27th Oct 20217:00 amRNSFinal Results
26th Oct 202111:18 amRNSNet Asset Value(s)
25th Oct 202111:43 amRNSNet Asset Value(s)
22nd Oct 202111:18 amRNSNet Asset Value(s)
21st Oct 202111:14 amRNSNet Asset Value(s)
20th Oct 202112:01 pmRNSNet Asset Value(s)
19th Oct 202111:57 amRNSNet Asset Value(s)
18th Oct 202111:54 amRNSNet Asset Value(s)
15th Oct 202111:28 amRNSNet Asset Value(s)
14th Oct 202111:29 amRNSNet Asset Value(s)
13th Oct 202111:30 amRNSNet Asset Value(s)
12th Oct 202111:23 amRNSNet Asset Value(s)
11th Oct 202111:24 amRNSNet Asset Value(s)
8th Oct 202111:33 amRNSNet Asset Value(s)
7th Oct 202111:14 amRNSNet Asset Value(s)
6th Oct 202111:32 amRNSNet Asset Value(s)
5th Oct 202111:47 amRNSNet Asset Value(s)
4th Oct 202111:40 amRNSNet Asset Value(s)
1st Oct 202111:56 amRNSNet Asset Value(s)
30th Sep 20214:57 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.